Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Placebo-controlled Study of Zilebesiran Add-on Therapy in Hypertension
2021-003776-13Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) comparing Zilebesiran add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Change from baseline at Month 3 in 24-hour mean systolic blood pressure by ABPM. Started Nov 2021; status: completed.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2021-003776-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003776-13.